StemCells, Inc. to Present at Harris Nesbitt Focus on Healthcare Confernece
PALO ALTO, Calif., (December 6, 2005) – StemCells, Inc. (NASDAQ: STEM) today announced that it will participate in the Harris Nesbitt Focus on Healthcare Conference scheduled for December 8, 2005, at the Millennium Broadway Hotel in New York City, New York. Martin McGlynn, President and Chief Executive Officer of StemCells, is scheduled to make a brief presentation and then participate in a panel discussion, all as part of the session, “Stem Cell-Based Medicine: The State of the Art” beginning at 1:30 p.m. on Thursday, December 8, 2005.
About StemCells, Inc.
StemCells, Inc. is a development stage biotechnology company focused on the discovery, development and commercialization of stem cell-based therapies to treat diseases of the nervous system, liver and pancreas. The Company’s stem cell programs seek to repair or repopulate neural or other tissue that has been damaged or lost as a result of disease or injury. StemCells is the first company to directly identify and isolate human neural stem cells from normal brain tissue. These stem cells are expandable into cell banks for therapeutic use, which demonstrates the feasibility of using normal, non-genetically modified cells as cell-based therapies. StemCells is the only publicly traded company solely focused on stem cell research and development and has approximately 40 U.S. and approximately 100 non-U.S. patents, as well as approximately 100 patent applications pending worldwide. Further information about the Company is available on its web site at: www.stemcellsinc.com.
Apart from statements of historical facts, the text of this press release constitutes forward-looking statements regarding, among other things, the future business operations of StemCells, Inc. (“the Company”). The forward-looking statements speak only as of the date of this news release. StemCells does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management’s current views and are based on certain assumptions that may or may not ultimately prove valid.
###
CONTACT: StemCells, Inc.
Rodney Young
Chief Financial Officer
650-475-3100, Ext. 105
or
Schwartz Communications, Inc.
781-684-0770 or 415-512-0770
stemcells@schwartz-pr.com
SOURCE: StemCells, Inc.
|
